Olfactory dysfunction, often overlooked despite its profound impact on quality of life, manifests in various forms ranging from partial loss (hyposmia) to complete anosmia. It can result from numerous insults, including viral infections, traumatic injuries, neurodegenerative diseases, and even age-related decline. Previously, therapeutic options were limited and largely ineffective, primarily focusing on symptomatic relief rather than addressing the underlying cellular deficits. The innovative use of NAD seeks to alter this paradigm by targeting the foundational neurochemical pathways responsible for olfactory receptor neuron regeneration and functional recovery.

Central to this new therapeutic strategy is NAD, a critical coenzyme found ubiquitously in living cells, essential for energy metabolism and enzymatic reactions related to cellular repair and renewal. Its role in the central nervous system is increasingly recognized, especially in modulating neurogenesis and protecting neurons from oxidative stress and mitochondrial dysfunction. By delivering NAD directly through the intranasal pathway, researchers harness the unique anatomical closeness of the nasal cavity to the olfactory bulb and the central nervous system, allowing for efficient, non-invasive drug delivery that bypasses the blood-brain barrier and targets affected regions directly.

The study meticulously delineated the pharmacokinetics and pharmacodynamics of intranasal NAD, revealing a robust uptake into olfactory tissues and subsequent enhancement of NAD+ dependent enzymatic activities. These enzymes, notably sirtuins and poly(ADP-ribose) polymerases (PARPs), play pivotal roles in cellular resilience and DNA repair mechanisms, which are crucial for maintaining the integrity and function of olfactory neurons. The restored enzymatic activity correlated strongly with improved olfactory sensory regeneration and functional improvements, as measured in behavioral olfactory tests conducted on experimental models.

Delving deeper into the molecular cascades, the researchers identified that NAD administration mitigates key pathological processes such as inflammatory cytokine release and oxidative damage, both notorious for exacerbating olfactory neuron degeneration. The anti-inflammatory effect is speculated to arise from NAD-mediated inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathways, which are heavily implicated in chronic neuroinflammation. By curbing these detrimental biochemical cascades, the intranasal NAD regimen creates a more conducive environment for neuroplasticity and cellular repair.

Crucially, the therapeutic regimen demonstrated a marked ability to stimulate the proliferation and differentiation of olfactory progenitor cells. These basal stem cells residing in the olfactory epithelium are the cellular source for continual regeneration of sensory neurons throughout life. The NAD treatment augmented the expression of key neurotrophic factors and growth-associated proteins, fostering a neurogenic niche that accelerates the replenishment of damaged or lost olfactory receptor neurons. This effect not only reinstated sensory capabilities but also preserved the architectural integrity of the olfactory system.

The implications of this study extend well beyond olfactory dysfunction, shedding light on the broader neuroregenerative potential of NAD in sensory and central nervous system disorders. Given that olfactory receptor neurons have direct projections to limbic structures involved in memory and emotion, restoring olfaction may also impart benefits in neuropsychiatric conditions linked to sensory deficits. The researchers propose that intranasal NAD could serve as a versatile platform for delivering regenerative therapies aimed at multiple neural circuits, thereby expanding therapeutic horizons in neurology.

In clinical terms, NAD’s safety profile is advantageous, with previous systemic applications revealing minimal adverse effects. The intranasal route further minimizes systemic exposure, reducing potential off-target impacts. The study reported no significant local irritation or toxicity, reinforcing the feasibility of this delivery method for repeated or long-term use. This is a critical consideration given the chronic nature of many olfactory dysfunction cases and the necessity for sustained therapeutic interventions.

Another remarkable aspect highlighted by the research is the rapid onset of action observed with NAD treatment. Patients and experimental subjects displayed measurable improvements within weeks rather than months, a stark contrast to previous treatments whose effects were either slow or negligible. This accelerated recovery timeline could transform patient management and rehabilitation protocols, facilitating earlier return to normal sensory function and improving psychological well-being, which is often severely compromised by anosmia.

Technological advancements in intranasal delivery devices also complement this pharmacological innovation, ensuring optimal dosing precision and bioavailability. Customized nasal applicators can maximize penetration to the olfactory cleft, overcoming anatomical barriers that have historically limited drug delivery efficacy in this region. Combined with NAD’s potent bioactivity, such targeted delivery strategies optimize therapeutic outcomes and patient compliance, setting a new standard for sensory disorder treatment modalities.

From a translational research perspective, the study underscores the importance of an integrative approach, combining molecular biology, pharmacology, and clinical testing to address complex sensory system dysfunctions. The collaboration among neuroscientists, otolaryngologists, and pharmacologists has been instrumental in refining the delivery method, optimizing dosage, and elucidating the biological underpinnings of NAD’s efficacy. This multidisciplinary synergy exemplifies the future trajectory of biomedical innovation tackling sensory and neurological disorders.

Looking forward, the research team plans to initiate expansive clinical trials involving diverse patient cohorts, including those with post-viral olfactory loss related to emerging respiratory viruses and neurodegenerative disease-linked anosmia. They aim to establish standardized treatment regimens and explore combinatorial therapies incorporating NAD with other regenerative agents or cognitive rehabilitation techniques. The ultimate goal is to integrate this therapeutic paradigm smoothly into routine clinical practice and provide a scalable solution to a global health concern.

The societal impact of effectively treating olfactory dysfunction cannot be overstated. The loss of smell profoundly affects nutrition, safety, and quality of life, often leading to diminished appetite, nutritional deficiencies, and a heightened risk of environmental hazard exposure. Psychological sequelae such as depression and social withdrawal are common. Thus, the arrival of an effective, accessible treatment like intranasal NAD opens new avenues for improving public health and patient quality of life worldwide.

In conclusion, the demonstration of NAD’s restorative power in the olfactory system marks a compelling advance in sensory medicine. By leveraging a naturally occurring molecule with critical roles in cellular metabolism and repair, delivered through an innovative intranasal approach, this therapy revitalizes damaged olfactory neurons and reinvigorates sensory function. Its rapid onset, favorable safety profile, and mechanistic specificity render it a promising candidate to become a cornerstone treatment for olfactory disorders, heralding a new era of neuroregenerative therapeutics.

The continued exploration of NAD’s multifaceted roles in neural maintenance and regeneration invites further inquiry and development. As this research gains momentum and moves through clinical validation stages, it carries the potential to redefine how sensory deficits are addressed, not only restoring senses lost but also enriching overall brain health and function. The intranasal NAD treatment thus stands at the forefront of a transformative wave in neurotherapeutics that may soon touch millions of lives.

Subject of Research: Therapeutic intervention for olfactory dysfunction via intranasal administration of nicotinamide adenine dinucleotide (NAD).

Article Title: Therapeutic effect of intranasal nicotinamide adenine dinucleotide in the restoration of olfactory dysfunction.

Article References:
Yoo, S.H., Jang, J.Y., Bae, J.S. et al. Therapeutic effect of intranasal nicotinamide adenine dinucleotide in the restoration of olfactory dysfunction. Experimental & Molecular Medicine (2026). https://doi.org/10.1038/s12276-026-01761-9

Image Credits: AI Generated

DOI: 01 July 2026

Nicotinamide adenine dinucleotide, a coenzyme found in all living cells, plays an essential role in metabolism, contributing to energy production and cellular repair mechanisms. Its precursors, such as nicotinamide riboside and nicotinamide mononucleotide, have gained attention because they can effectively elevate NAD+ levels in the brain. The restoration of NAD+ levels is believed to counteract the biochemical processes that lead to neuronal damage and cognitive decline. Understanding the extent of these effects requires a rigorous examination of existing literature, which encompasses various rodent models that mimic human cognitive disorders.

The systematic review conducted by Qader et al. aggregates data from numerous preclinical studies to assess the efficacy of NAD+ precursors on cognitive function. By reviewing these studies, the researchers aimed to evaluate not only the feasibility of these treatments but also their mechanisms of action. The review concludes that substantial evidence supports the hypothesis that enhancing NAD+ levels can lead to significant improvements in cognitive performance, particularly when administered at earlier stages of neurodegeneration.

In the study, the benefits of NAD+ precursors in mitigating cognitive disease were analyzed through behavioral assessments in rodent models. These assessments provided vital insights into improvements in memory, learning capabilities, and overall cognitive function. Remarkably, the findings revealed that higher doses of NAD+ precursors were generally associated with more pronounced cognitive enhancements. However, the researchers emphasized that optimal dosing strategies require careful consideration to maximize therapeutic outcomes without triggering adverse effects — a complex balance that adds layers to the overarching narrative of NAD+ as a cognitive enhancer.

Moreover, the review outlined the biochemical pathways influenced by NAD+ pathogens. The elevation of NAD+ directly affects key signaling pathways that govern neuronal survival and plasticity. For instance, SIRT1, a NAD+-dependent protein deacetylase, is crucial for maintaining synaptic function and cognitive resilience. The activation of SIRT1 leads to enhanced neuroprotective responses, further underscoring the vital role of NAD+ in cognitive health. These findings illuminate how molecular mechanisms intertwine with observable behavioral improvements, painting a more comprehensive picture of NAD+ in neuroscience.

Interestingly, the implications of the review extend beyond mere cognitive enhancement in animal models; they also touch on potential human applications. Given the alarming rise in cognitive-related diseases among older adults, the prospect of utilizing NAD+ precursors as preventive or therapeutic agents beckons further exploration and clinical validation. While preliminary findings in rodents show promise, a concerted effort must follow for these insights to translate effectively into clinical practice for human patients.

As neuroscience continues to unlock the mysteries surrounding cognitive disorders, the integration of nutritional supplements aimed at elevating NAD+ levels appears to hold substantial promise. Future clinical trials will be pivotal for establishing the respective efficacy, safety, and appropriate dosing regimens for human populations. If trials yield positive results, NAD+ precursors could emerge as vital components of a comprehensive strategy for managing cognitive decline, offering new hope to patients and their caregivers.

In conclusion, the systematic review by Qader et al. not only highlights the therapeutic potential of NAD+ precursors but also underscores the critical need for ongoing research in this area. With cognitive decline presenting increasingly prevalent challenges, understanding the nuances of NAD+ metabolism, its impact on the brain, and the scope of its therapeutic applications remains paramount. As the field of neurodegenerative disease research advances, the incorporation of such nutritional interventions alongside traditional therapies may revolutionize patient care and improve quality of life for millions affected by cognitive diseases.

As public interest grows in proactive approaches to brain health, discussing the science behind NAD+ could pave the way for more awareness and acceptance of dietary supplements as adjunct therapies. The future may well see a paradigm shift in how cognitive health is approached, with knowledge derived from animal research guiding innovations in human clinical settings.

This converging landscape of bioenergetics and cognitive health presents an exciting frontier in neuroscience. With research endeavors focused on understanding the intricate workings of NAD+ and its precursors, promising pathways are emerging for not only treatment but potentially prevention strategies against cognitive decline. As we await the outcomes of forthcoming human studies, the time is ripe for scientists, clinicians, and advocates alike to champion the cause of brain health, making informed choices based on the ground-breaking research that continues to unfold.

Ultimately, the implications of this research extend beyond the confines of academia; they spark hope across communities grappling with the burden of cognitive disorders. By empowering individuals with knowledge of how NAD+ plays a role in cognitive function, we can ignite a movement rooted in scientific discovery that may transform the lives of those increasingly affected by these debilitating conditions.

Research like that conducted by Qader and colleagues continues to inspire a more profound understanding of the biological underpinnings of cognition while reminding us of the dated, yet invaluable, saying: An ounce of prevention is worth a pound of cure. By harnessing the power of NAD+ precursors, there exists a golden opportunity to change the narrative surrounding cognitive health, fostering resilience and vitality in the aging brain.

Subject of Research: Nicotinamide adenine dinucleotide (NAD+) precursors for cognitive diseases

Article Title: A systematic review of the therapeutic potential of nicotinamide adenine dinucleotide precursors for cognitive diseases in preclinical rodent models

Article References:

Qader, M.A., Hosseini, L., Abolhasanpour, N. et al. A systematic review of the therapeutic potential of nicotinamide adenine dinucleotide precursors for cognitive diseases in preclinical rodent models.
BMC Neurosci 26, 17 (2025). https://doi.org/10.1186/s12868-025-00937-9

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12868-025-00937-9

Keywords: NAD+, cognitive diseases, preclinical models, Alzheimer’s disease, neurology

NAD⁺ is a coenzyme found in every living cell and acts as a crucial metabolic regulator, often likened to a cellular “fuel gauge.” It orchestrates a diverse array of biological processes, including cellular respiration, DNA repair, and maintenance of mitochondrial function. As organisms age, NAD⁺ concentrations demonstrably wane, correlating with weakened cellular resilience, diminished energy metabolism, and increased vulnerability to neurodegenerative and cardiovascular disorders. This age-related NAD⁺ depletion is not merely a biomarker but appears to be a fundamental driver of physiological decline, making it a prime target for therapeutic intervention.

The article thoroughly examines how NAD⁺ biosynthesis pathways can be augmented pharmacologically. Compounds such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — both vitamin B3 derivatives — have emerged as leading supplements capable of elevating systemic NAD⁺ levels. Preclinical studies in animal models have yielded promising results, demonstrating enhanced cognitive function, improved muscle performance, and better metabolic profiles. However, the authors emphasize that human clinical trials remain in their infancy and present a heterogeneous landscape requiring rigorous standardization and replication to confirm efficacy and safety.

One core focus of this review is the intricate balance required in NAD⁺ modulation. Dr. Jianying Zhang, one of the key authors, highlights that while augmenting NAD⁺ holds therapeutic potential, understanding the optimal dose-response relationship is critical. Over-supplementation might have unexpected consequences given NAD⁺’s involvement in multiple signaling pathways. Hence, long-term safety profiles coupled with personalized medicine approaches are necessary to tailor NAD⁺-enhancement strategies to individual patients.

Importantly, the article serves as a clarion call for multidisciplinary collaboration. Despite NAD⁺’s fundamental biological importance, the field is plagued by fragmented data and commercial hype that cloud scientific judgment. By consolidating the current knowledge base, this consensus aims to provide researchers and clinicians with a structured framework to navigate ongoing clinical trials and exploratory research. The authors advocate for unified protocols, larger sample sizes, and stratification strategies that acknowledge interindividual variability, such as genetic differences, lifestyle factors, and comorbidities.

The timing of this review is particularly pertinent. Globally, a surge of clinical trials are underway testing NAD⁺ precursors in various contexts — from neurodegeneration and cardiovascular disease to metabolic syndromes. The public and commercial enthusiasm for these supplements has surged in parallel, sometimes eclipsing the delicate nuances of underlying biology. The experts caution against premature conclusions and stress the necessity of empirical evidence to substantiate claims. Their balanced outlook underscores the need to discern which NAD⁺-boosting agents are most effective and to identify clinical scenarios where intervention yields meaningful outcomes.

On a mechanistic level, NAD⁺ acts as a substrate for sirtuins, PARPs (poly ADP-ribose polymerases), and other enzymes pivotal in genome stability and cellular stress responses. These enzymatic activities orchestrate processes integral to longevity and disease resistance. The depletion of NAD⁺ impairs these critical functions, accelerating senescence and deterioration. Thus, strategies that restore NAD⁺ are not merely symptom-targeting but may halt or reverse foundational processes in the aging trajectory. Nonetheless, translating molecular insights into clinically viable treatments remains an intricate endeavor.

The review does not shy away from discussing the challenges confronting the field. Variability in bioavailability, tissue-specific NAD⁺ metabolism, and potential off-target effects remain unknowns. Furthermore, the authors recognize the potential for NAD⁺ metabolism to interact with other age-related pathways and emphasize the importance of integrative research that considers the broader physiological network. Regulatory frameworks and ethical considerations around NAD⁺-based therapies add further complexity, especially as commercial interests accelerate product availability.

Norwegian contributors, including Sofie Lautrup, Hilde Loge Nilsen, Leiv Otto Watne, and others, collaborated closely with international experts from Denmark, Japan, the United States, and beyond. Their collective expertise spans clinical neurology, cardiology, molecular biology, and aging research, lending unparalleled depth to the review. This global effort not only synthesizes decades of research but sets an ambitious agenda for the years ahead.

One noteworthy aspect is the transparent disclosure of potential conflicts of interest, notably by senior author Dr. Evandro Fei Fang-Stavem, who maintains ties with commercial entities developing NAD⁺ precursor technologies. The authors assert that their expert opinion is grounded in rigorous scientific evaluation and aim to delineate clear, evidence-based guidance free from commercial bias. This candidness strengthens the credibility of their conclusions.

In conclusion, this comprehensive expert opinion elucidates how NAD⁺ modulation stands at the frontier of aging research. While the therapeutic potential is undeniably compelling, the field demands a disciplined, evidence-driven approach. By highlighting current knowledge gaps, defining methodological standards, and fostering international collaboration, the authors contribute a critical roadmap for transforming the biology of NAD⁺ into viable treatments. Future breakthroughs may ultimately redefine how we approach age-related diseases and harness the power of cellular metabolism to promote healthy longevity.

Subject of Research: People

Article Title: Emerging strategies, applications and challenges of targeting NAD+ in the clinic

News Publication Date: 9-Sep-2025

Web References: DOI: 10.1038/s43587-025-00947-6

References:
Zhang J, Wang H-L, Lautrup S, Nilsen HL, Treebak JT, Watne LO, Selbæk G, Wu LE, Omland T, Pirinen E, Cheung TC, Wang J, Ziegler M, Tysnes O-B, Zapata-Pérez R, Bruzzone S, Cantó C, Deleidi M, Janssens GE, Houtkooper RH, Scheibye-Knudsen M, Koshizaka M, Yokote K, Verdin E, Bohr VA, Tzoulis C, Sinclair DA & Fang EF. Emerging strategies, applications and challenges of targeting NAD⁺ in the clinic. Nature Aging (Published online 9 September 2025).

Keywords: NAD⁺, aging, metabolism, nicotinamide riboside, nicotinamide mononucleotide, sirtuins, DNA repair, neurodegeneration, clinical trials, mitochondrial function, longevity, metabolic health